NEW MEDICINAL FORM OF AMOXICILLIN/KLAVULANAT


Cite item

Full Text

Abstract

Amoxicillin/clavulanic acid is accessible in the pharmaceutical market more than 20 years, and currently is one of the most prescribed antibacterial preparations at a wide spectrum of infections in clinical practice. Popularity of this drug is caused by its pharmacokinetic and pharmacodinamic properties. One of modern forms Amoxicillin/clavulanic acid is modified-release film-coated tablets with high concentration of antibiotic and improved pharmacokinetic characteristics.

References

  1. Rolinson GN. 6-APA and development of the β-lactam antibiotis. J Antimicrob Chemother 1979;5:7-14.
  2. Rolinson GN. Forty years of β-lactam research. J Antimicrob Chemother 1998;41:589-603.
  3. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940;373:837.
  4. Poole K. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 2004;61:2200-23.
  5. Bush К, Jacoby G, Medeiros A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
  6. Reading C, Cole M. Ctavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977;11(5):852-57.
  7. Maiti SN, Phillips OA, Micetich RG, et al. Beta-lactamase inhibitors: agents to overcome bacterial resistance. Curr Med Chem 1998; 5:441-56.
  8. Kazmierczak A. β-Lactamase Inhibitors. In: Antibacterial and antifungal Agents. Bryskier A, editor. ASM-Press (Washington DC), 2005.
  9. Comber KR, Horton R, Mizen L, et al. Activity of amoxicillin/clavulanic acid (2:1) [BRL 25000, Augmentin] in vitro and in vivo. In Current Chemotherapy and Infectious Disease. Proceedings of the Eleventh International Congress of Chemotherapy and the Nineteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1980. pp. 343-4. American Society for Microbiology, Washington, DC, USA.
  10. Cooper CE, Slocombe B, White AR. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxicillin against β-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 1990;26:371-80.
  11. Slocombe B, Beale A, Boon RJ, et al. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid. Postgraduate Medicine 1984;(Suppl.):29-49.
  12. Ninane G, Joly J, Kraftman M, et al. Bronchopulmonary infection due to β-lactamase-producing Branhamella catarrhalis treated with amoxicillin/clavulanic acid. Lancet 1978;ii:257.
  13. Goldstein FW, Kitzis MD, Acar JF. Effect of clavulanic acid and amoxicillin formulation against β-lactamase-producing Gram-negative bacteria in urinary tract infections. J Antimicrob Chemother 1979;5:705-09.
  14. Ball AP, Geddes AM, Davey PG. et al. Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study. Lancet 1980;i: 620-23.
  15. Martinelli R, Lopes AA, de Oliveria MM. et al. Amoxicillin-clavulanic acid in treatment of urinary tract infection due to gram-negative bacteria resistant to penicillin. Antimicrob Agents Chemother 1981; 20:800-02.
  16. Leigh DA, Bradnock K, Marriner JM. Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to β-lactamase producing bacteria. Journal of Antimicrobial Chemotherapy 1981;7:229-36.
  17. Benard Y, Lemenager J, Morel C. A comparative study of amoxycillin and Augmentin in the treatment of bronchopulmonary infections. In Augmentin, Clavulanate-Potentiated Amoxycillin. Proceedings of the European Symposium, Scheveningen, The Netherlands, 1982. Current Clinical Practice 1983;4:282-88. Excerpta Medica, Amsterdam, The Netherlands.
  18. Aten EM, Neu HC. A multicenter, double blind, comparative study of amoxicillin/clavulanic acid and cefaclor in the treatment of skin and skin structure infections. Postgraduate Medicine 1984;(Suppl.):147-55.
  19. Available from http://www.regmed.ru/
  20. Bryskier A. Penicillins. In: Antibacterial and antifungal Agents. Ed. Bryskier A. ASM-Press (Washington DC), 2005.
  21. Finlay J, Miller L, Poupard JA. A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother 2003;52(1):18-23.
  22. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cehalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999;43:882-89.
  23. Deshpande LM, Fritsche TR, Jones RN. Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2004;49:231-36.
  24. Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog 2002;85:57-72.
  25. Casellas JM, Arenoso HJ, Soutric JL, et al. Estudio comparative in vitro e in vivo de tres asociaciones suicidas de betalactamasas con aminopenicilinas. Rev Esp Quimioter 1993;6:289-97.
  26. Chambers HF. Other beta-lactam antibiotics. In: Mandell G.L., Bennet J.E., Dolin R., editors. Principles and Practice of Infectious Diseases. Churchill Livingstone, 6th edition, 2004:311-18.
  27. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность S. pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспек-тивных исследований ПеГАС-I и ПеГАС-II // Клиническая микробиология и антимикробная химиотерапия. 2006. № 8. С. 33-47.
  28. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность S. pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. // Клиническая микробиология и антимикробная химиотерапия // 2005. № 7. С. 154-166.
  29. Kozlov RS, Sivaja OV. Antimicrobial resistance of clinical H. influenzae in Russia: results of prospective multicenter study (PEhASus). Proceedings of the 8th European Congress of Chemotherapy and Infection. Budapest, Hungary 26-28 October, 2006. P. 280.
  30. Jackson D, Cooper DL, Hardy DL, et al. Pharmacokinetic, toxicological and metabolic studies with Augmentin. In Augmentin: Proceedings of the First Symposium, 1980 (Rolinson, G. N. & Watson, A., Eds). Excerpta Medica, Amsterdam, The Netherlands. 1980;87-105.
  31. Haginaka J, Nakagawa T, Nishino Y, et al. High performance liquid chromatographic determination of clavulanic acid in human urine. Journal of Antibiotics (Tokyo) 1981;34:1189-94.
  32. Kaye CM, Allen A, Perry S, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001;23:578-84
  33. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7(Suppl. 1):S13-S20.
  34. Berry V, Singley C, Satterfeld J, et al. Effcacy of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate against experimental respiratory tract infection (RTI) in rats caused by Streptococcus pneumoniae (Sp). Poster presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22-25, 2001; Chicago, IL.
  35. Craig WA. Proof of concept: performance testing in models. Clin Microb Infect 2004;10(Suppl. 2):12-17.
  36. Козлов Р.С. Пневмококки: уроки прош-лого - взгляд в будущее. Смоленск: МАКМАХ, 2010.
  37. Augmentin XRTM, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA, 2002.
  38. File T, Lode H, Crann R, and Group ATS. Comparative efficacy/safety of pharmacoknetically enhanced amoxicillin/clavulanate 200/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). Presented at the 99th International Conference of the American Thoracic Society. 16, 2003.
  39. File TM, Jacobs MR, Poole MD, et al. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin|clavulanate. Int J Antimicrob Agents 2002;20:235-47.
  40. Практическое руководство по антиинфекционной химиотерапии / Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. М., 2007. 464 с.
  41. Практические рекомендации по применению антибиотиков у детей в амбулаторной практике / Под ред. Баранова А.А., Страчунского Л.С. М., 2006.
  42. Neu HC, Wilson APR, Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993;5:67-93.
  43. Briggs CG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. Williams & Wilkins, 1994.
  44. Berkovitch M, Diav-Citrin O, Greenberg R, et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol 2004; 58(3):298-302.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies